Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director · See Remarks | May 07, 2026 | May 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 415,973 |
Reported balance
After 2026-05-11 transaction · row 1
1 source rowRow 1 · 2026-05-11 · Conversion · Acquired 27,386 · Balance 415,973 F1: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F2: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-11 · Conversion · Disposed 100,000 · Balance 0 F1: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F3: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-11 · Conversion · Disposed 166,116 · Balance 0 F2: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F3: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 884,450 |
Reported balance
After 2026-05-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-07 · Grant · Acquired 884,450 · Balance 884,450 F4: Option vests in forty-eight (48) equal monthly installments, with the first installment scheduled to vest on June 7, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
F2: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
F3: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
F4: Option vests in forty-eight (48) equal monthly installments, with the first installment scheduled to vest on June 7, 2026, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2026 Filed May 12, 2026 00:30 UTC | Odyssey Therapeutics, Inc. ODTX · Entity 4850 | ConversionSeries D Convertible Preferred Stock · Derivative | 166,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-217585 · ownership.xml · derivative · entry 3 Glick Gary D · CIK 0002051249 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,095 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F2 · price: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F2 · derivative.exercise_date: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F2 · derivative.expiration_date: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F3 · derivative.underlying_shares: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. Read SEC document |
| May 11, 2026 Filed May 12, 2026 00:30 UTC | Odyssey Therapeutics, Inc. ODTX · Entity 4850 | ConversionSeries C Convertible Preferred Stock · Derivative | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-217585 · ownership.xml · derivative · entry 2 Glick Gary D · CIK 0002051249 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,291 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F1 · price: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F1 · derivative.exercise_date: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F1 · derivative.expiration_date: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F3 · derivative.underlying_shares: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. Read SEC document |
| May 11, 2026 Filed May 12, 2026 00:30 UTC | Odyssey Therapeutics, Inc. ODTX · Entity 4850 | ConversionCommon Stock | 27,386 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-217585 · ownership.xml · nonDerivative · entry 1 Glick Gary D · CIK 0002051249 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F2 · price: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. Read SEC document |
| May 07, 2026 Filed May 12, 2026 00:30 UTC | Odyssey Therapeutics, Inc. ODTX · Entity 4850 | GrantStock Option (Right to Buy) · Derivative | 884,450 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001193125-26-217585 · ownership.xml · derivative · entry 4 Glick Gary D · CIK 0002051249 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 884,450 Underlying: Common Stock · 884,450 shares Expires 2036-05-06 F4 · derivative.exercise_date: Option vests in forty-eight (48) equal monthly installments, with the first installment scheduled to vest on June 7, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.